4/2/21 UPDATE: Due to new COVID-19 restrictions in Victoria overnight, this event is now VIRTUAL-ONLY. Please read below for further details.
In the wake of 2020, we are all too aware of what’s NOThot in the health industry and wider community. This year, our annual ‘Hot or Not’ event will focus on what is HOT in the sector, with a selection of speakers showcasing the growth and advancement of business, diagnostics, therapeutics and more heading into 2021. On the back of a year that has challenged us all, join us for a discovery of hot trends in the sector for the year ahead. Our panel of speakers will discuss:
2021 insights from Phillips Ormonde Fitzpatrick
Businesses thriving remotely
Future business and innovation
Cancer therapeutic discovery
Date: Thursday 4 February 2021 Time: 4:00 pm – 5:25 pm AEDT Presentations and Q&A Format (online): An access link will be provided prior to the event. Registration: Online: Members: $35; The Grid community: $35; Non-members: $45 (purchase below)
Unsure if your organisation is a member? Check our member directory
IN-PERSON TICKET HOLDERS
This event is now running online-only. Your registration will be transferred to a virtual ticket and you will receive a Zoom event link to access the event. A refund for the difference of cost ($40) will be actioned. If you do not wish to view online, a full refund of $75 will be made – please contact email@example.com to arrange this.
VIRTUAL TICKET HOLDERS
Due to the switch to online-only, this event will now be hosted using a different platform. Please disregard the link provided in yesterday’s confirmation email – you will receive a Zoom link to join the webinar today.
The above information has also been communicated to ticket holders via email. Please be patient as we transfer both in-person and virtual registrations to Zoom – you will receive a link prior to the event commencing this afternoon. If you have any queries please contact our office via the contact information in our most recent email.
Dr Danielle Burns, Senior Associate, Phillips Ormonde Fitzpatrick Andrew Carter, Managing Director, Commercial Eyes Rhys Hayes, Chief Executive Officer + Founder of IE Group, Founding Member of The Grid Michael Johnson, Chief Executive Officer and Managing Director, Rhinomed Ltd Lisa Dubé, Acting Chief Executive Officer, Cancer Therapeutics CRC
With thanks to our partner organisation, The Grid.
Dr Danielle Burns, Senior Associate, Phillips Ormonde Fitzpatrick
Danielle has extensive experience as a patent attorney with expertise in patent strategy, protection and enforcement in the Biotech sector. She has a strong understanding of global patent and regulatory exclusivities (including data and market exclusivities) and has facilitated entry of several biopharmaceuticals (including antibodies and antisense molecules), diagnostics, cellular therapeutics, and agricultural products (including transgenic plants) to market.
Danielle is involved in the preparation and prosecution of patent applications globally; patent due-diligence; and provides patentability, infringement, clearance, and validity opinions. Danielle has also been involved in opposition and litigation disputes involving multiple stakeholders.
Danielle has a diverse client base – working with several local and overseas biotech companies, including small to medium entities, big pharmaceutical companies and generics companies as well as academic institutions to strategically protect their intellectual property and facilitate market entry.
Danielle has industry experience, having worked as a postdoctoral scientist at BIO21 involved in the expression and purification of proteins involved in Influenza-specific viral immunity. She graduated from The University of Melbourne with a BSc (Hons) majoring in Biochemistry and Immunology. She was awarded the Australian Society for Microbiology 3rd Year Prize, the Exhibition Prize for Microbiology and the Peter J Doos Award. Danielle also completed a PhD in Immunology at The University of Melbourne which examined the impact of natural variation in genes that control immunity; showed how very slight differences in certain immune response genes result in dramatic changes in the response to viral infection.
Andrew Carter, Managing Director, Commercial Eyes
Andrew is the founder and Managing Director of Commercial Eyes Pty Ltd and has 30 plus years commercial experience working in the pharmaceutical and medical technology industry. In 2014, Andrew received the Australian medicine industry’s most prestigious honour, the ‘Pat Clear Award’, in recognition of the significant role he, and Commercial Eyes, has played in supporting companies to bring important medicines into the Australian market.
Andrew established Commercial Eyes Pty Ltd in 2001. Today, the company employs over 100 staff, and has grown to become the foremost pharmaceutical and medical technology commercialisation firm in Australia and New Zealand. In August 2012, Commercial Eyes was recognised as one of the leading ‘medium sized’ businesses in Australia as a finalist in the Telstra Business Awards.
Andrew is the President of ARCS Australia Ltd; a member of the Medicines Australia Advisory Council and University of Melbourne, Masters of Biotechnology Advisory Board. He is the immediate past Chair of the BioMelbourne Network Inc and has chaired and been a member of numerous industry association committees including Industry Policy, Strategy, Access, Quality Use of Medicines and Continuing Education and is a former member of the National Prescribing Service, Medicines Industry Liaison Group.
In addition to Andrew’s health technology industry roles, he is particularly interested in social justice and disadvantage and was Chairman of Melbourne City Mission, a trustee of the Dr. John Singleton Trust and a former Councillor of Whitley College, University of Melbourne. He has also chaired various advisory boards and committees for The Salvation Army. In February 2010, Andrew was featured in the AICD’s Directors Social Impact Study and shared his experiences as a Not for Profit non-executive director. He is a regular presenter and speaker at AICD member briefings and events.
Andrew has an undergraduate degree in Science and post graduate degrees in Business and Commercial Law.
Rhys Hayes, Chief Executive Officer + Founder of IE Group, Founding Member of The Grid
Rhys Hayes is the Founder and CEO of IE, an independent innovation company that works with corporate teams to launch new ideas to market. He is a serial entrepreneur and host of Silicon Block.
Rhys will share the vision, purpose and opportunities of The Grid with BioMelbourne audience.
The Grid, a nod in name to Robert Hoddle's 1837 business-friendly CBD street design (Hoddle Grid), is a global festival for future business and ideas to be hosted in Melbourne in 2022 and held annually. The Grid will bring together the best innovators, business leaders, change makers, government allies and pioneers of the future once a year, supercharging Victoria and Australia’s position on the global business stage.
The Grid is a for-profit social enterprise, governed, first and foremost by its mission to drive economic growth and prosperity for the state of Victoria.
Michael Johnson, Chief Executive Officer and Managing Director, Rhinomed Ltd
Michael is an experienced leader and innovator who has specialised in the successful commercialisation of emerging technologies and brands for over 20 years. Michael has worked in and for a wide spectrum of companies from ASX300 through to start-up companies in Life Sciences, Cleantech, Financial Services, Energy and Utilities, Manufacturing, Marketing and Communication. Michael’s most recent work has focused on helping companies envision and create new growth and innovation, manage and grow technology platforms and achieve sustainable growth through business model innovation.
Michael has been a Principal at two leading global consulting firms where he advised on innovation and competing in heavily regulated industries. Prior to that he held senior roles within some of the world’s most successful marketing and communication firms where he launched a number of high profile new products and brands. Michael received a Masters in Entrepreneurship and Innovation from Swinburne University and a Bachelor’s degree with distinction in Business from Monash University.
Lisa Dubé, Acting Chief Executive Officer, Cancer Therapeutics CRC
Ms Lisa Dubé is an experienced business leader in the biotech sector and has been the Acting Chief Executive Officer of Cancer Therapeutics since August 2020. She also held the role of Business Director and Company Secretary since joining Cancer Therapeutics in February 2018.
She has extensive experience in management and research including governance, finance and quality control. Prior to joining Cancer Therapeutics, Lisa held the position of Business Manager for the CRC for Mental Health and managed the research and commercialisation of mental health biomarkers. Lisa started her career in research laboratories and has worked overseas and within Australia at the Burnet Institute, the Walter and Eliza Hall Institute and the Australian Genome Research Facility.
Lisa has a BSc in Biochemistry, an MBA from the University of Victoria, Canada and is a graduate of the Australian Institute of Company Directors.